Research ExplorerPublicationsComparability of input parameters in the German Retina.net R...

Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry - An exemplary comparison between 2011 and 2021

Standard

Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry - An exemplary comparison between 2011 and 2021. / Winter, K; Pfeil, J M; Engmann, H; Aisenbrey, S; Lorenz, B; Hufendiek, K; Breuss, H; Khattab, M; Süsskind, D; Kakkassery, V; Lagrèze, W A; Barth, T; Liegl, R; Bründer, M C; Skevas, C; Goldammer, I; Glitz, B; Michalewicz, E; Krohne, T U; Bartmann, I R; Stahl, A; Retina.net ROP and EU-ROP registry study groups.

In: ACTA OPHTHALMOL, Vol. 102, No. 3, 05.2024, p. e314-e321.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Winter, K, Pfeil, JM, Engmann, H, Aisenbrey, S, Lorenz, B, Hufendiek, K, Breuss, H, Khattab, M, Süsskind, D, Kakkassery, V, Lagrèze, WA, Barth, T, Liegl, R, Bründer, MC, Skevas, C, Goldammer, I, Glitz, B, Michalewicz, E, Krohne, TU, Bartmann, IR, Stahl, A & Retina.net ROP and EU-ROP registry study groups 2024, 'Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry - An exemplary comparison between 2011 and 2021', ACTA OPHTHALMOL, vol. 102, no. 3, pp. e314-e321. https://doi.org/10.1111/aos.15753

APA

Winter, K., Pfeil, J. M., Engmann, H., Aisenbrey, S., Lorenz, B., Hufendiek, K., Breuss, H., Khattab, M., Süsskind, D., Kakkassery, V., Lagrèze, W. A., Barth, T., Liegl, R., Bründer, M. C., Skevas, C., Goldammer, I., Glitz, B., Michalewicz, E., Krohne, T. U., ... Retina.net ROP and EU-ROP registry study groups (2024). Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry - An exemplary comparison between 2011 and 2021. ACTA OPHTHALMOL, 102(3), e314-e321. https://doi.org/10.1111/aos.15753

Vancouver

Winter K, Pfeil JM, Engmann H, Aisenbrey S, Lorenz B, Hufendiek K et al. Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry - An exemplary comparison between 2011 and 2021. ACTA OPHTHALMOL. 2024 May;102(3):e314-e321. https://doi.org/10.1111/aos.15753

Bibtex

@article{cfdee3388b6f4d33b3d121701acbf2d8,
title = "Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry - An exemplary comparison between 2011 and 2021",
abstract = "PURPOSE: The German Retina.net ROP registry and its Europe-wide successor, the EU-ROP registry, collect data from patients treated for ROP. This analysis compares input parameters of these two registries to establish a procedure for joint analyses of different registry data using exemplary datasets from the two registries.METHODS: Exemplary datasets from the two databases over a 1-year period each (German Retina.net ROP Registry, 2011, 22 infants; EU-ROP Registry, 2021, 44 infants) were compared. The parameters documented in the two databases were aligned and analysed regarding demographic parameters, treatment modalities, complications within first 24 h and retreatments.RESULTS: The current analysis showed that data can be aligned for joint analyses with some adjustments within the data structure. The registry with more detailed data collection (EU-ROP) needs to be reduced regarding granularity in order to align the different registries, as the registry with lower granularity determines the level of analyses that can be performed in a comparative approach. In the exemplary datasets, we observed that the overall most common ROP severity in both registries was zone II, 3+ (2011: 70.5%; 2021: 65%), with decreasing numbers of clock hours showing preretinal neovascularisations (2011: 10-12 clock hours in 29% of cases, 2021: 4-6 clock hours in 38%). The most prevalent treatment method was laser coagulation in 2011 (75%) and anti-VEGF therapy in 2021 (86.1%). Within the anti-VEGF group, all patients were treated with bevacizumab in 2011 and with ranibizumab in 2021. Retreatment rates were comparable in 2011 and 2021.CONCLUSION: Data from two different ROP registries can be aligned and jointly analysed. The analysis reveals a paradigm shift in treatment modalities, from predominantly laser to anti-VEGF, and within the anti-VEGF group from bevacizumab to ranibizumab in Germany. In addition, there was a trend towards earlier treatment in 2021.",
author = "K Winter and Pfeil, {J M} and H Engmann and S Aisenbrey and B Lorenz and K Hufendiek and H Breuss and M Khattab and D S{\"u}sskind and V Kakkassery and Lagr{\`e}ze, {W A} and T Barth and R Liegl and Br{\"u}nder, {M C} and C Skevas and I Goldammer and B Glitz and E Michalewicz and Krohne, {T U} and Bartmann, {I R} and A Stahl and {Retina.net ROP and EU-ROP registry study groups}",
note = "{\textcopyright} 2023 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.",
year = "2024",
month = may,
doi = "10.1111/aos.15753",
language = "English",
volume = "102",
pages = "e314--e321",
journal = "ACTA OPHTHALMOL",
issn = "1755-375X",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry - An exemplary comparison between 2011 and 2021

AU - Winter, K

AU - Pfeil, J M

AU - Engmann, H

AU - Aisenbrey, S

AU - Lorenz, B

AU - Hufendiek, K

AU - Breuss, H

AU - Khattab, M

AU - Süsskind, D

AU - Kakkassery, V

AU - Lagrèze, W A

AU - Barth, T

AU - Liegl, R

AU - Bründer, M C

AU - Skevas, C

AU - Goldammer, I

AU - Glitz, B

AU - Michalewicz, E

AU - Krohne, T U

AU - Bartmann, I R

AU - Stahl, A

AU - Retina.net ROP and EU-ROP registry study groups

N1 - © 2023 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.

PY - 2024/5

Y1 - 2024/5

N2 - PURPOSE: The German Retina.net ROP registry and its Europe-wide successor, the EU-ROP registry, collect data from patients treated for ROP. This analysis compares input parameters of these two registries to establish a procedure for joint analyses of different registry data using exemplary datasets from the two registries.METHODS: Exemplary datasets from the two databases over a 1-year period each (German Retina.net ROP Registry, 2011, 22 infants; EU-ROP Registry, 2021, 44 infants) were compared. The parameters documented in the two databases were aligned and analysed regarding demographic parameters, treatment modalities, complications within first 24 h and retreatments.RESULTS: The current analysis showed that data can be aligned for joint analyses with some adjustments within the data structure. The registry with more detailed data collection (EU-ROP) needs to be reduced regarding granularity in order to align the different registries, as the registry with lower granularity determines the level of analyses that can be performed in a comparative approach. In the exemplary datasets, we observed that the overall most common ROP severity in both registries was zone II, 3+ (2011: 70.5%; 2021: 65%), with decreasing numbers of clock hours showing preretinal neovascularisations (2011: 10-12 clock hours in 29% of cases, 2021: 4-6 clock hours in 38%). The most prevalent treatment method was laser coagulation in 2011 (75%) and anti-VEGF therapy in 2021 (86.1%). Within the anti-VEGF group, all patients were treated with bevacizumab in 2011 and with ranibizumab in 2021. Retreatment rates were comparable in 2011 and 2021.CONCLUSION: Data from two different ROP registries can be aligned and jointly analysed. The analysis reveals a paradigm shift in treatment modalities, from predominantly laser to anti-VEGF, and within the anti-VEGF group from bevacizumab to ranibizumab in Germany. In addition, there was a trend towards earlier treatment in 2021.

AB - PURPOSE: The German Retina.net ROP registry and its Europe-wide successor, the EU-ROP registry, collect data from patients treated for ROP. This analysis compares input parameters of these two registries to establish a procedure for joint analyses of different registry data using exemplary datasets from the two registries.METHODS: Exemplary datasets from the two databases over a 1-year period each (German Retina.net ROP Registry, 2011, 22 infants; EU-ROP Registry, 2021, 44 infants) were compared. The parameters documented in the two databases were aligned and analysed regarding demographic parameters, treatment modalities, complications within first 24 h and retreatments.RESULTS: The current analysis showed that data can be aligned for joint analyses with some adjustments within the data structure. The registry with more detailed data collection (EU-ROP) needs to be reduced regarding granularity in order to align the different registries, as the registry with lower granularity determines the level of analyses that can be performed in a comparative approach. In the exemplary datasets, we observed that the overall most common ROP severity in both registries was zone II, 3+ (2011: 70.5%; 2021: 65%), with decreasing numbers of clock hours showing preretinal neovascularisations (2011: 10-12 clock hours in 29% of cases, 2021: 4-6 clock hours in 38%). The most prevalent treatment method was laser coagulation in 2011 (75%) and anti-VEGF therapy in 2021 (86.1%). Within the anti-VEGF group, all patients were treated with bevacizumab in 2011 and with ranibizumab in 2021. Retreatment rates were comparable in 2011 and 2021.CONCLUSION: Data from two different ROP registries can be aligned and jointly analysed. The analysis reveals a paradigm shift in treatment modalities, from predominantly laser to anti-VEGF, and within the anti-VEGF group from bevacizumab to ranibizumab in Germany. In addition, there was a trend towards earlier treatment in 2021.

U2 - 10.1111/aos.15753

DO - 10.1111/aos.15753

M3 - SCORING: Journal article

C2 - 37725047

VL - 102

SP - e314-e321

JO - ACTA OPHTHALMOL

JF - ACTA OPHTHALMOL

SN - 1755-375X

IS - 3

ER -